Latest Regulatory News

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.

Donaco International posted modest revenue and EBITDA gains in Q2 FY2025, alongside a stronger cash position, while navigating regulatory uncertainties in Southeast Asia.

Tigers Realm Coal is finalising the sale of its Russian subsidiaries for US$49 million, pending crucial Presidential approval, while navigating recent leadership shifts.

St Barbara has secured A$100 million to fast-track its Simberi Sulphides project, aiming to bring forward production by up to five months, even as Q2 gold output fell short of expectations due to operational challenges.

Meeka Metals reports steady progress on its Murchison Gold Project, with key infrastructure and processing plant expansions on track for first gold production by mid-2025.

Omni Bridgeway Limited reports strong investment proceeds and new commitments in the first half of FY25, alongside significant cost savings and the imminent financial close of Fund 9 with Ares Management.

Almonty Industries has locked in final commitments for an AUD 18.45 million equity placement from existing shareholders, aiming to strengthen its financial position and cover offer costs. The placement includes warrants and options, with closing pending regulatory approval.

Paradigm Biopharmaceuticals has appointed Advanced Clinical as the Clinical Research Organisation for its critical Phase 3 trial targeting knee osteoarthritis pain, setting the stage for patient recruitment and dosing in Q2 2025.

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.

Matsa Resources is poised to commence mining at its Devon Pit Gold Mine after securing all regulatory approvals and raising fresh capital. The company targets delivering its final feasibility study in the March 2025 quarter, marking a critical step toward production.

Medical Developments International has posted a robust improvement in operating cash flow and revenue for Q2 FY25, driven by higher demand and pricing for its flagship product Penthrox across Australia and Europe.

Summit Minerals reports significant progress at its Equador Niobium and Tantalum Project, highlighted by strong assay results and permit submissions, while temporarily suspending drilling at its newly launched Barra Lithium Project due to mechanical setbacks.